PNC-27 is a chimeric peptide that combines the p53 MDM-2 binding domain with a leader sequence derived from the HDM-2-interacting region of p14ARF — designed to selectively penetrate and destroy cancer cell membranes while leaving normal cells unaffected. The selectively mechanism exploits a property unique to cancer cells: the aberrant expression of MDM-2 (murine double minute 2) protein on the plasma membrane of malignant cells, which is not found on normal cell membranes. PNC-27 binds to this membrane-expressed MDM-2, causing rapid and selective disruption of cancer cell plasma membranes.

The design of PNC-27 represents an elegant approach to cancer cell specificity. MDM-2 is well-characterized as the primary negative regulator of p53 — it binds to p53's transactivation domain in the nucleus to ubiquitinate and degrade p53. In cancer cells, MDM-2 is frequently overexpressed and, crucially, aberrantly trafficked to the plasma membrane — a translocation not observed in normal non-cancerous cells. PNC-27's p53 homologous peptide domain binds to this membrane-expressed MDM-2, while the leader sequence drives membrane penetration, resulting in pore formation and membrane disruption specifically in MDM-2-expressing cancer cells.

In vitro and in vivo preclinical studies have demonstrated PNC-27's selective cytotoxicity across multiple cancer cell lines: pancreatic adenocarcinoma, breast cancer, leukemia, melanoma, and others expressing membrane MDM-2. The cytotoxic mechanism is direct membrane disruption — cancer cells treated with PNC-27 undergo rapid necrosis rather than the slower apoptotic cell death, suggesting pore formation as the primary killing mechanism. Critically, normal cell lines exposed to the same PNC-27 concentrations show no significant cytotoxicity — the selectivity index (cancer/normal cell kill ratio) is high.

The peptide has progressed through preclinical development under the research of the Cooper laboratory and collaborators, with in vivo mouse tumor models demonstrating tumor growth inhibition following PNC-27 treatment. These studies demonstrate that the MDM-2 membrane expression selectivity translates from in vitro cell culture to living tumor microenvironments — the mechanism functions in the complex tissue context, not just simplified cell culture conditions.

PNC-27 is a research compound — it has not entered human clinical trials. Its significance lies in demonstrating a proof-of-concept cancer cell selectivity mechanism based on membrane MDM-2 targeting, and as a research tool for investigating MDM-2 membrane expression biology. The 30mg vial provides a substantial research quantity for in vitro experimentation. Research applications include: MDM-2 membrane expression studies, selective cytotoxicity assays in cancer cell lines, combination therapy research with conventional chemotherapeutics, and investigation of membrane disruption mechanisms in malignant cells.

This is a research compound for laboratory use. Not for human administration.